- Home
- AMRN vs CYBN Comparison
AMRN vs CYBN Comparison
Compare AMRN & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- CYBN
- Stock Information
- Founded
- AMRN 1989
- CYBN 2019
- Country
- AMRN Ireland
- CYBN Canada
- Employees
- AMRN N/A
- CYBN N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- CYBN Pharmaceuticals and Biotechnology
- Sector
- AMRN Health Care
- CYBN Health Care
- Exchange
- AMRN Nasdaq
- CYBN Nasdaq
- Market Cap
- AMRN 216.0M
- CYBN 178.7M
- IPO Year
- AMRN 1993
- CYBN N/A
- Fundamental
- Price
- AMRN $14.52
- CYBN $7.69
- Analyst Decision
- AMRN Strong Sell
- CYBN Strong Buy
- Analyst Count
- AMRN 1
- CYBN 4
- Target Price
- AMRN $12.00
- CYBN $85.00
- AVG Volume (30 Days)
- AMRN 88.3K
- CYBN 426.5K
- Earning Date
- AMRN 07-30-2025
- CYBN 08-12-2025
- Dividend Yield
- AMRN N/A
- CYBN N/A
- EPS Growth
- AMRN N/A
- CYBN N/A
- EPS
- AMRN N/A
- CYBN N/A
- Revenue
- AMRN $219,361,000.00
- CYBN N/A
- Revenue This Year
- AMRN N/A
- CYBN N/A
- Revenue Next Year
- AMRN N/A
- CYBN N/A
- P/E Ratio
- AMRN N/A
- CYBN N/A
- Revenue Growth
- AMRN N/A
- CYBN N/A
- 52 Week Low
- AMRN $7.08
- CYBN $4.81
- 52 Week High
- AMRN $17.49
- CYBN $13.88
- Technical
- Relative Strength Index (RSI)
- AMRN 42.13
- CYBN 48.21
- Support Level
- AMRN $14.45
- CYBN $7.26
- Resistance Level
- AMRN $15.61
- CYBN $8.18
- Average True Range (ATR)
- AMRN 0.60
- CYBN 0.44
- MACD
- AMRN -0.30
- CYBN -0.04
- Stochastic Oscillator
- AMRN 5.88
- CYBN 27.22
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.